Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume

Liver International

Volumn 34, Issue 10, 2014, Pages 1578-1583

  Wijnands, Titus F M ^a   Neijenhuis, Myrte K ^a   Kievit, Wietske ^a   Nevens, Frederik ^b   Hogan, Marie C ^c   Torres, Vicente E ^c   Gevers, Tom J G ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Mayo Clinic   (United States)

Author keywords

Health related quality of life; Liver volume; Polycystic liver disease; Symptoms

Indexed keywords

SOMATOSTATIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; DYSPNEA; FEMALE; HEALTH SURVEY; HUMAN; LIVER POLYCYSTIC DISEASE; LIVER WEIGHT; LOWER ABDOMINAL PAIN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; SYMPTOM; UPPER ABDOMINAL PAIN; ABDOMINAL PAIN; CYST; LIVER; LIVER DISEASE; NONPARAMETRIC TEST; PATHOLOGY; PSYCHOLOGY;

ABDOMINAL PAIN; CROSS-SECTIONAL STUDIES; CYSTS; HEALTH SURVEYS; HUMANS; LIVER; LIVER DISEASES; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC;

EID: 84908120955     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12430     Document Type: Article

References (30)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-301.
2. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122-30.
3. Bae KT, Zhu F, Chapman AB, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomaldominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol 2006; 1: 64-9.
4. van Keimpema L, de Koning DB, van Hoek B, et al. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int 2011; 31: 92-8.
5. Everson GT, Taylor MR, Doctor RB. Polycystic disease of the liver. Hepatology 2004; 40: 774-82.
6. Sherstha R, McKinley C, Russ P, et al. Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease. Hepatology 1997; 26: 1282-6.
7. Torres VE. Treatment of polycystic liver disease: one size does not fit all. Am J Kidney Dis 2007; 49: 725-8.
8. Gevers TJ, Drenth JP. Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol 2013; 10: 101-8.
9. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology 2010; 52: 2223-30.
10. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 137: 1661-8.e1-2.
11. Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J A Soc Nephrol 2010; 21: 1052-61.
12. Chrispijn M, Nevens F, Gevers TJ, et al. The long-term outcome of patients with polycystic liver disease treated with lanreotide. Aliment Pharmacol Ther 2012; 35: 266-74.
13. Chrispijn M, Gevers TJ, Hol JC, et al. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol 2013; 59: 153-9.
14. Hogan MC, Masyuk TV, Page L, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant 2012; 27: 3532-9.
15. Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 2001; 96: 2199-205.
16. Revicki DA, Wood M, Maton PN, Sorensen S. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 252-8.
17. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
18. Ware JE. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: New England Medical Center, Health Institute, 1993.
19. Ware JE Jr. SF-36 health survey update. Spine 2000; 25: 3130-9.
20. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: Health Institute, New England Medical Center; 1994.
21. Ware JE JR, Gandek B, Kosinski M, et al. The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. J Clin Epidemiol 1998; 51: 1167-70.
22. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055-68.
23. Bovenschen HJ, Janssen MJ, van Oijen MG, et al. Evaluation of a gastrointestinal symptoms questionnaire. Dig Dis Sci 2006; 51: 1509-15.
24. Kirchner GI, Rifai K, Cantz T, et al. Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl 2006; 12: 1268-77.
25. Schnelldorfer T, Torres VE, Zakaria S, Rosen CB, Nagorney DM. Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2009; 250: 112-8.
26. Gall TM, Oniscu GC, Madhavan K, Parks RW, Garden OJ. Surgical management and longterm follow-up of non-parasitic hepatic cysts. HPB (Oxford) 2009; 11: 235-41.
27. Wehler M, Reulbach U, Nichterlein R, et al. Healthrelated quality of life in chronic pancreatitis: a psychometric assessment. Scand J Gastroenterol 2003; 38: 1083-9.
28. Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20(Suppl. 7): 31-9.
29. Dan AA, Younossi ZM. Quality of life and liver transplantation in patients with polycystic liver disease. Liver Transpl 2006; 12: 1184-5.
30. Hoevenaren IA, Wester R, Schrier RW, et al. Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int 2008; 28: 264-70.